Holen Sie sich die Stockscreener-App
2.48
3.13%
-0.08
Schlusskurs vom Vortag:
$2.56
Offen:
$2.48
24-Stunden-Volumen:
4.32M
Relative Volume:
0.76
Marktkapitalisierung:
$604.57M
Einnahmen:
$22,000
Nettoeinkommen (Verlust:
$-190.89M
KGV:
-2.8565
EPS:
-0.8682
Netto-Cashflow:
$-149.63M
1W Leistung:
+2.90%
1M Leistung:
-6.42%
6M Leistung:
+92.25%
1J Leistung:
+72.22%
1-Tages-Spanne:
$2.45
$2.66
1-Wochen-Bereich:
$2.20
$2.67
52-Wochen-Spanne:
$0.8621
$2.80
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Firmenname
Allogene Therapeutics Inc
Sektor
Branche
Telefon
(650) 457-2700
Adresse
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.48 | 604.57M | 22,000 | -190.89M | -149.63M | -0.8682 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-05-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-08-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-28 | Bestätigt | B. Riley Securities | Buy |
| 2021-10-20 | Eingeleitet | Cowen | Outperform |
| 2021-10-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-10-08 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Fortgesetzt | Jefferies | Buy |
| 2021-05-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-26 | Hochstufung | Stifel | Hold → Buy |
| 2020-12-10 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-11-24 | Eingeleitet | BofA Securities | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-06-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-19 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Herabstufung | SunTrust | Buy → Hold |
| 2020-04-13 | Eingeleitet | SunTrust | Buy |
| 2020-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-24 | Eingeleitet | Berenberg | Hold |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-05 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-23 | Eingeleitet | Stifel | Hold |
| 2019-03-29 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten
Allogene Therapeutics SVP sells $13k in stock - Investing.com
Allogene Therapeutics (ALLO) SVP sells shares in tax-related sell-to-cover - Stock Titan
Chart Watch: What are the future prospects of Allogene Therapeutics Inc2026 Big Picture & Entry Point Strategy Guides - baoquankhu1.vn
Allogene Therapeutics (NASDAQ: ALLO) notice to sell 2,867 shares - Stock Titan
Allogene Therapeutics (NASDAQ:ALLO) Shares Up 11.9%What's Next? - MarketBeat
Why Allogene Therapeutics (ALLO) says its lead cancer program is still on track in 2026 - MSN
ALLO Technical Analysis & Stock Price Forecast - intellectia.ai
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 earnings call transcript - MSN
If You Invested $1,000 in Allogene Therapeutics (ALLO) - Stock Titan
Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026 - Yahoo Finance
5 Penny Stocks with Potential to Rise 1000 Percent - Insider Monkey
Risk Check: Will Allogene Therapeutics Inc benefit from geopolitical trends2026 Biggest Moves & Real-Time Buy Zone Alerts - baoquankhu1.vn
Allogene Therapeutics advances CAR T therapy to expand access for patients - Traders Union
Piper Sandler analysts bullish on Allogene Therapeutics (ALLO) ahead of key ALPHA3 data readout - MSN
ALLO Technical Analysis | Trend, Signals & Chart Patterns | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - chartmill.com
Worthington Steel Posts Downbeat Earnings, Joins MillerKnoll And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Allogene Therapeutics (NASDAQ:ALLO) Upgraded at Truist Financial - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Down 9.2%Here's Why - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Allogene Therapeutics (NASDAQ:ALLO) Shares Up 11.4%Time to Buy? - MarketBeat
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index - marketscreener.com
Allogene targets pivotal ALPHA3 data in April and extends cash runway into 2028 while prioritizing scalable CAR T programs - MSN
Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout - Insider Monkey
Allogene Therapeutics (NASDAQ:ALLO) SVP Sells $11,942.45 in Stock - MarketBeat
David Chang Sells 47,763 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock - MarketBeat
Allogene (NASDAQ: ALLO) SVP share sale funds tax withholding - Stock Titan
Allogene (ALLO) CEO executes 47,763-share tax sell-to-cover transaction - Stock Titan
Allogene Therapeutics targets new approach to autoimmune conditions with ALLO-329 - Traders Union
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Down 5.1%Time to Sell? - MarketBeat
Take the Zacks approach to beat the markets: Starbucks, Amgen, Allogene in focus - MSN
Form 144 Allogene Therapeutics For: 16 March By Investing.com - Investing.com Australia
Allogene Therapeutics (NASDAQ: ALLO) proposes sale of 4,835 shares - Stock Titan
Allogene Therapeutics (NASDAQ: ALLO) RSUs Vest, 47,763 Common Shares - Stock Titan
ALLO Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
Citizens reiterates Allogene stock rating on pipeline progress By Investing.com - Investing.com South Africa
Citizens reiterates Allogene stock rating on pipeline progress - Investing.com
Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Expands By 19.8% - MarketBeat
Allogene Therapeutics Banks on 2026 Trial Catalysts - The Globe and Mail
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
El Pollo Loco Posts Upbeat Q4 Results, Joins Kyivstar Group, American Public Education And Other Big Stocks Moving Higher On Friday - Sahm
Analysts Are Bullish on Top Healthcare Stocks: Equillium (EQ), Qiagen (QGEN) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Allogene Therapeutics (ALLO) - The Globe and Mail
Finanzdaten der Allogene Therapeutics Inc-Aktie (ALLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.49%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):